| 16.35 0.33 (2.06%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.73 | 1-year : | 23.83 |
| Resists | First : | 18.61 | Second : | 20.4 |
| Pivot price | 17.65  |
|||
| Supports | First : | 15.69 | Second : | 13.06 |
| MAs | MA(5) : | 16.55 |
MA(20) : | 17.95 |
| MA(100) : | 17.3 |
MA(250) : | 10.12 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 9.7 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 25.77 | Low : | 3.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GLUE ] has closed above bottom band by 14.5%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.93 - 17.04 | 17.04 - 17.14 |
| Low: | 16.03 - 16.18 | 16.18 - 16.31 |
| Close: | 16.13 - 16.35 | 16.35 - 16.55 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Mon, 16 Mar 2026
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st
Mon, 16 Mar 2026
GLUE SEC Filings - Monte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 16 Mar 2026
Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha
Mon, 16 Mar 2026
Advanced prostate cancer trial tests MRT-2359 with J&J’s ERLEADA - Stock Titan
Mon, 16 Mar 2026
Monte Rosa Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Thu, 12 Mar 2026
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 95.3 (%) |
| Shares Short | 9,330 (K) |
| Shares Short P.Month | 5,550 (K) |
| EPS | 0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.98 |
| Profit Margin | 11.5 % |
| Operating Margin | -258.3 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | 9.2 % |
| Qtrly Rev. Growth | 38.5 % |
| Gross Profit (p.s.) | 0.66 |
| Sales Per Share | 2.38 |
| EBITDA (p.s.) | 0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 149 (M) |
| Levered Free Cash Flow | 49 (M) |
| PE Ratio | 51.09 |
| PEG Ratio | 0 |
| Price to Book value | 4.1 |
| Price to Sales | 6.86 |
| Price to Cash Flow | 8.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|